- Investopedia•1 hour ago
Safety concerns have re-emerged after a patient died in Roche’s hemophilia trial.
- Accesswire•3 hours agoBlog Coverage Novartis Gains Priority Review from the FDA for its Cancer Drug Zykadia as a Frontline Treatment for ALK-positive Non-Small Cell Lung Cancer
Upcoming AWS Coverage on Shire PLC Post-Earnings Results LONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS ) as the Company announced ...
- PR Newswire•4 hours agoCHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of Conditional Marketing Authorisation for Natpar (rhPTH[1-84]), a recombinant human protein with the full length 84-amino-acid sequence of endogenous parathyroid hormone (PTH), as an adjunctive treatment for adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone. Hypoparathyroidism, a designated orphan disease by the European Commission (EC), is a rare disease that occurs when inadequate levels of PTH are secreted by the parathyroid glands, resulting in a mineral imbalance in the body expressed by a low concentration of calcium (hypocalcemia) and high concentration of phosphate (hyperphosphatemia) in the blood.
SHP.L : Summary for SHIRE PLC ORD 5P - Yahoo Finance
Shire plc (SHP.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,848.50 x 51000|
|Ask||4,849.50 x 53800|
|Day's Range||4,838.00 - 4,944.50|
|52 Week Range||2,707.19 - 5,377.00|
|PE Ratio (TTM)||117.11|
|Dividend & Yield||0.26 (0.44%)|
|1y Target Est||N/A|